Mythen in der Kinderrheumatologie – Stimmt es eigentlich, dass…?

Mirjam Freudenhammer; Markus Hufnagel

doi:10.1055/a-2421-3178

Arthritis und Rheuma, Table of Contents

Arthritis und Rheuma 2024; 44(06): 406-413
DOI: 10.1055/a-2421-3178

Schwerpunkt

Mythen in der Kinderrheumatologie – Stimmt es eigentlich, dass…?

Infektionen

Authors

Mirjam Freudenhammer

¹Sektion Pädiatrische Rheumatologie und Klinische Infektiologie, Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Freiburg, Medizinische Fakultät, Universität Freiburg, Freiburg

²IMM-PACT Clinician Scientist Programm, Medizinische Fakultät, Universität Freiburg, Freiburg
Markus Hufnagel

¹Sektion Pädiatrische Rheumatologie und Klinische Infektiologie, Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Freiburg, Medizinische Fakultät, Universität Freiburg, Freiburg

Abstract

ZUSAMMENFASSUNG

Infektionen und Impfungen spielen in der Kinderrheumatologie in mehrfacher Hinsicht eine wichtige Rolle und sorgen sowohl bei Kinderärzten als auch bei Eltern regelmäßig für Verunsicherung. So wird gemeinhin davon ausgegangen, dass Patienten mit rheumatischen Erkrankungen, insbesondere unter antirheumatischer Medikation, eine erhöhte Anfälligkeit für Infektionen aufweisen. Daher kommt insbesondere Impfungen zur Prävention von Infektionen eine zentrale Rolle zu. Gleichzeitig würden die meisten Kinderrheumatologen aus Erfahrung wohl zustimmen, dass Infektionen oder Impfungen Schübe triggern können. Und dann kommt Infektionen nach der Hygienehypothese sogar möglicherweise eine präventive Funktion zu…? Einige der verbreiteten Annahmen werden im vorliegenden Artikel etwas genauer unter die Lupe genommen und auf ihre Evidenz hin überprüft

Schlüsselwörter

Infektionen - Impfungen - Kinderrheumatologie - rheumatische Erkrankungen

Full Text

References

Literatur
1 Doran MF, Crowson CS, Pond GR. et al Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum 2002; 46: 2287-2293 https://doi.org/10.1002/art.10524
2 Jung J-Y, Yoon D, Choi Y. et al Associated clinical factors for serious infections in patients with systemic lupus erythematosus. Sci Rep 2019; 9: 9704 https://doi.org/10.1038/s41598-019-46039-5
3 Beukelman T, Xie F, Chen L. et al Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64: 2773-2780 https://doi.org/10.1002/art.34458
4 Udaondo C, Núñez Cuadros E, Murias S. et al Are infections in children with juvenile idiopathic arthritis more frequent than in healthy children? A prospective multicenter observational study. Front Pediatr 2022; 10: 917731
5 Salonen PH, Säilä H, Salonen JH. et al Pneumonia in children with juvenile idiopathic arthritis in Finland 1999–2014: a nationwide retrospective register linkage study. Clin Exp Rheumatol 2018; 36 (03) 502-507
6 Aeschlimann FA, Chong S-L, Lyons TW. et al Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses. J Pediatr 2019; 204: 162-171.e3 https://doi.org/10.1016/j.jpeds.2018.08.065
7 Becker I, Horneff G. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry. Arthritis Care Res 2017; 69: 552-560 https://doi.org/10.1002/acr.22961
8 McLean-Tooke A, Aldridge C, Waugh S. et al Methotrexate, rheumatoid arthritis and infection risk – what is the evidence?. Rheumatology 2009; 48: 867-871 https://doi.org/10.1093/rheumatology/kep101
9 Nimmrich S, Horneff G. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Rheumatol Int 2015; 35: 465-470 https://doi.org/10.1007/s00296-014-3197-6
10 Zhang N, Wilkinson S, Riaz M. et al Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin Exp Rheumatol 2012; 30: 962-371
11 Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatol Oxf Engl 2006; 45: 1370-1375 https://doi.org/10.1093/rheumatology/kel328
12 Perricone C, Ceccarelli F, Matteo S. et al Porphyromonas gingivalis and rheumatoid arthritis. Curr Opin Rheumatol 2019; 31: 517 https://doi.org/10.1097/BOR.0000000000000638
13 Hanlon P, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther 2014; 16: R3 https://doi.org/10.1186/ar4429
14 Rigante D, Bosco A, Esposito S. The Etiology of Juvenile Idiopathic Arthritis. Clin Rev Allergy Immunol 2015; 49: 253-261 https://doi.org/10.1007/s12016-014-8460-9
15 Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol 2009; 155: 1 https://doi.org/10.1111/j.1365-2249.2008.03834.x
16 Sharma V, Sharma A. Infectious mimics of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2022; 36: 101736 https://doi.org/10.1016/j.berh.2021.101736
17 Naddei R, Alfani R, Bove M. et al Increased Relapse Rate During COVID-19 Lockdown in an Italian Cohort of Children With Juvenile Idiopathic Arthritis. Arthritis Care Res 2023; 75: 326-331 https://doi.org/10.1002/acr.24768
18 Conti G, Galletta F, Carucci NS. et al Negative effect of lockdown on juvenile idiopathic arthritis patients. Clin Rheumatol 2021; 40: 3723-3727 https://doi.org/10.1007/s10067-021-05694-8
19 Hügle B, Krumrey-Langkammerer M, Haas J-P. Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication. Pediatr Rheumatol 2021; 19: 163 https://doi.org/10.1186/s12969-021-00653-8
20 Sengler C, Eulert S, Minden K. et al Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany. RMD Open 2021; 7: e001687 https://doi.org/10.1136/rmdopen-2021-001687
21 Roux CH, Brocq O, Gerald F. et al Impact of Home Confinement During the COVID-19 Pandemic on Medication Use and Disease Activity in Spondyloarthritis Patients. Arthritis Rheumatol Hoboken NJ 2020; 72: 1771-1772 https://doi.org/10.1002/art.41397
22 Di Iorio M, Cook CE, Vanni KMM. et al DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Semin Arthritis Rheum 2022; 55: 152025 https://doi.org/10.1016/j.semarthrit.2022.152025
23 Hadiyen F el, Tsang-A-Sjoe MWP, Lissenberg-Witte BI. et al Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus. Lupus Sci Med 2024; 11: e001131 https://doi.org/10.1136/lupus-2023-001131
24 Torres-Ruiz J, Barrera-Vargas A, Ortiz-Hernández R. et al Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study. Lupus 2018; 27: 312-318 https://doi.org/10.1177/0961203317720527
25 Joo YB, Kim K-J, Park K-S, Park Y-J. Influenza infection as a trigger for systemic lupus erythematosus flares resulting in hospitalization. Sci Rep 2021; 11: 4630 https://doi.org/10.1038/s41598-021-84153-5
26 Jansen MH, Rondaan C, Legger G. et al Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations. Front Pediatr 2022; 10 https://doi.org/10.3389/fped.2022.910026
27 Ohm M, van Straalen JW, Zijlstra M. et al Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study. Vaccine 2023; 41: 3782-3789 https://doi.org/10.1016/j.vaccine.2023.04.056
28 Jaeger VK, Hoffman HM, van der Poll T. et al Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatol Oxf Engl 2017; 56: 1484-1491 https://doi.org/10.1093/rheumatology/kex185
29 Heshin-Bekenstein M, Ziv A, Toplak N. et al Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatol Oxf Engl. 2022; keac103 https://doi.org/10.1093/rheumatology/keac103
30 Akgün Ö, Çakmak F, Guliyeva V. et al Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. Rheumatol Oxf Engl 2022; keac140 https://doi.org/10.1093/rheumatology/keac140
31 Heshin-Bekenstein M, Ziv A, Toplak N. et al Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. Vaccines 2023; 11: 819 https://doi.org/10.3390/vaccines11040819
32 Lawson-Tovey S, Machado PM, Strangfeld A. et al SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry. RMD Open 2022; 8: e002322 https://doi.org/10.1136/rmdopen-2022-002322
33 Opoka-Winiarska V, Lipinska J, Michalak A. et al Safety of the COVID-19 vaccination in children with juvenile idiopathic arthritis – A observational study from two pediatric rheumatology centres in Poland. Front Pediatr 2023; 11: 1103763 https://doi.org/10.3389/fped.2023.1103763
34 Farisogullari B, Lawson-Tovey S, Hyrich KL. et al Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry. Ann Rheum Dis 2024 https://doi.org/10.1136/ard-2024-225869
35 Carlson D, Hernandez J, Bloom BJ. et al Lack of Borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum 1999; 42: 2705-2709 https://doi.org/10.1002/1529-0131(199912)42 12 < 2705::AIDL42:DASHANR29 > 3.0.CO;2L42:DASHHL42:URLEND
36 Tory HO, Zurakowski D, Sundel RP. Outcomes of children treated for Lyme arthritis: results of a large pediatric cohort. J Rheumatol 2010; 37: 1049-1055 https://doi.org/10.3899/jrheum.090711
37 Bentas W, Karch H, Huppertz HI. Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy. J Rheumatol 2000; 27: 2025-2030
38 Morbach H, Holl-Wieden A, Dirks J. et al Lyme-Arthritis. Arthritis Rheuma 2022; 42: 185-192 https://doi.org/10.1055/a-1825-7194
39 Arvikar SL, Crowley JT, Sulka KB, Steere AC. Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease. Arthritis Rheumatol Hoboken NJ 2017; 69: 194 https://doi.org/10.1002/art.39866
40 Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 2006; 54: 3079-3086 https://doi.org/10.1002/art.22131
41 Nimmrich S, Becker I, Horneff G. Intraarticular corticosteroids in refractory childhood Lyme arthritis. Rheumatol Int 2014; 34: 987-994 https://doi.org/10.1007/s00296-013-2923-9
42 Lochhead RB, Strle K, Arvikar SL. et al Lyme arthritis: linking infection, inflammation and autoimmunity. Nat Rev Rheumatol 2021; 17: 449 https://doi.org/10.1038/s41584-021-00648-5
43 Lochhead RB, Arvikar SL, Aversa JM. et al Robust interferon signature and suppressed tissue repair gene expression in synovial tissue from patients with post-infectious, Borrelia burgdorferi-induced Lyme arthritis. Cell Microbiol 2018; 21: e12954 https://doi.org/10.1111/cmi.12954
44 Dirks J, Fischer J, Klaussner J. et al Disease-specific T cell receptors maintain pathogenic T helper cell responses in postinfectious Lyme arthritis. J Clin Invest 2024; 134 https://doi.org/10.1172/JCI179391
45 Jutras BL, Lochhead RB, Kloos ZA. et al Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis. Proc Natl Acad Sci U S A 2019; 116: 13498-13507 https://doi.org/10.1073/pnas.1904170116
46 Strle K, Jones KL, Drouin EE. et al Borrelia burgdorferi RST1 (OspC Type A) Genotype Is Associated with Greater Inflammation and More Severe Lyme Disease. Am J Pathol 2011; 178: 2726 https://doi.org/10.1016/j.ajpath.2011.02.018
47 Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med 1990; 323: 219-223 https://doi.org/10.1056/NEJM199007263230402
48 Strle K, Shin JJ, Glickstein LJ, Steere AC. A Toll-like Receptor 1 Polymorphism Is Associated with Heightened T-helper 1 Inflammatory Responses and Antibiotic-Refractory Lyme Arthritis. Arthritis Rheum 2012; 64: 1497 https://doi.org/10.1002/art.34383
49 Sulka KB, Strle K, Crowley JT. et al Correlation of Lyme Disease-Associated IgG4 Autoantibodies With Synovial Pathology in Antibiotic-Refractory Lyme Arthritis. Arthritis Rheumatol Hoboken NJ 2018; 70: 1835-1846 https://doi.org/10.1002/art.40566
50 Nordal E, Zak M, Aalto K. et al Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 2809-2818 https://doi.org/10.1002/art.30426
51 Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 2006; 54: 3079-3086 https://doi.org/10.1002/art.22131
52 Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107: 725-731 https://doi.org/10.7326/0003-4819-107-5-725
53 Rose NR. The Adjuvant Effect in Infection and Autoimmunity. Clin Rev Allergy Immunol 2008; 34: 279-282 https://doi.org/10.1007/s12016-007-8049-7
54 Scher JU, Littman DR, Abramson SB. Review: Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. Arthritis Rheumatol 2016; 68: 35-45 https://doi.org/10.1002/art.39259
55 Bizjak M, Blazina Š, Zajc Avramovič M. et al Vaccination coverage in children with rheumatic diseases. Clin Exp Rheumatol 2020; 38: 164-170
56 Morin M-P, Quach C, Fortin É, Chédeville G. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology 2012; 51: 2046-2050 https://doi.org/10.1093/rheumatology/kes175
57 Minden K, Niewerth M, Borte M. et al Impfungen bei rheumatischen Erkrankungen des Kindes- und Jugendalters. Z Für Rheumatol 2007; 66: 111-120 https://doi.org/10.1007/s00393-007-0150-z
58 Davies K. Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology 2002; 41: 937-941 https://doi.org/10.1093/rheumatology/41.8.937
59 Papailiou S, Markade A, Eleftheriou I. et al A National Survey Across Primary Care Pediatricians Regarding Immunization Views and Practices in Children With Rheumatic Diseases. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 2021; 27: e588-90 https://doi.org/10.1097/RHU.0000000000001251
60 Jansen MHA, Rondaan C, Legger GE. et al EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis 2023; 82: 35-47 https://doi.org/10.1136/annrheumdis-2022-222574
61 Aikawa NE, França ILA, Ribeiro AC. et al Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine 2015; 33: 604-609 https://doi.org/10.1016/j.vaccine.2014.12.030
62 Çakmak F, Çakan M, Demir F. et al Hepatitis B vaccination response of treatment-naive patients with juvenile idiopathic arthritis. Rheumatol Int 2022; 42: 1199-1205 https://doi.org/10.1007/s00296-021-04833-3
63 Jensen L, Nielsen S, Christensen AE. et al Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study. Pediatr Rheumatol Online J 2021; 19: 26 https://doi.org/10.1186/s12969-021-00518-0
64 Keller M, Pittet LF, Zimmermann P. Immunogenicity and safety of routine vaccines in children and adolescents with rheumatic diseases on immunosuppressive treatment – a systematic review. Eur J Pediatr 2022; 181: 1329-1362 https://doi.org/10.1007/s00431-021-04283-w
65 Blanchard-Rohner G. Vaccination in Children With Autoimmune Disorders and Treated With Various Immunosuppressive Regimens: A Comprehensive Review and Practical Guide. Front Immunol 2021; 12: 711637 https://doi.org/10.3389/fimmu.2021.711637
66 Maritsi D, Vartzelis G, Soldatou A, Garoufi A, Spyridis N. Markedly decreased antibody titers against hepatitis B in previously immunised children presenting with juvenile idiopathic arthritis. Clin Exp Rheumatol 2013; 31: 969-973
67 Heijstek MW, Scherpenisse M, Groot N. et al Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis 2014; 73: 1500-1507 https://doi.org/10.1136/annrheumdis-2013-203429
68 Cheent K, Nolan J, Shariq S. et al Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s Disease. J Crohns Colitis 2010; 4: 603-605 https://doi.org/10.1016/j.crohns.2010.05.001
69 Whittembury A, Ramirez G, Hernández H. et al Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009; 27: 5974-5981 https://doi.org/10.1016/j.vaccine.2009.07.082
70 Wagner N, Assmus F, Arendt G. et al Impfen bei Immundefizienz. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz 2019; 62: 494-515 https://doi.org/10.1007/s00103-019-02905-1
71 Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology 2009; 48: 144-148 https://doi.org/10.1093/rheumatology/ken436
72 Heijstek MW, Pileggi GCS, Zonneveld-Huijssoon E. et al Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 1384-1387 https://doi.org/10.1136/ard.2006.063586
73 Heijstek MW, Kamphuis S, Armbrust W. et al Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 2013; 309: 2449-2456 https://doi.org/10.1001/jama.2013.6768
74 Heijstek MW, van Gageldonk PGM, Berbers GAM, Wulffraat NM. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis 2012; 71: 948-954 https://doi.org/10.1136/annrheumdis-2011-200637
75 Uziel Y, Moshe V, Onozo B. et al Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection. Vaccine 2020; 38: 2198-2201 https://doi.org/10.1016/j.vaccine.2020.01.037
76 Miyamoto M, Ono E, Barbosa C. et al Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus. Lupus 2011; 20: 736-744 https://doi.org/10.1177/0961203310397409
77 Çakmak F, Akgün Ö, Demirkan FG. et al Live-attenuated measles, mumps, and rubella booster vaccine in children diagnosed with rheumatic disease: A single-center study. Eur J Pediatr 2023; 182: 135-140 https://doi.org/10.1007/s00431-022-04646-x
78 Horneff G, Burgos-Vargas R, Constantin T. et al Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2013; 73: 1114 https://doi.org/10.1136/annrheumdis-2012-203046
79 García-Doval I, Pérez-Zafrilla B, Descalzo MA. et al Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010; 69: 1751-1755 https://doi.org/10.1136/ard.2009.125658
80 Groot N, Pileggi G, Sandoval CB. et al Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment. Vaccine 2017; 35: 2818-2822 https://doi.org/10.1016/j.vaccine.2017.04.015
81 Barbosa CMPL, Terreri MTRA, Rosário PO. et al Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clin Exp Rheumatol 2012; 30: 791-798
82 Speth F, Hinze CH, Andel S. et al Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list. Pediatr Rheumatol Online J 2018; 16: 15 https://doi.org/10.1186/s12969-018-0231-3
83 Toplak N, Avčin T. Long-term safety and efficacy of varicella vaccination in children with juvenile idiopathic arthritis treated with biologic therapy. Vaccine 2015; 33: 4056-4059 https://doi.org/10.1016/j.vaccine.2015.06.086
84 Pileggi GS, de Souza CBS, Ferriani VPL. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res 2010; 62: 1034-1039 https://doi.org/10.1002/acr.20183